• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Alma G. Sorensen, MD


  • Pinho MC, Polaskova P, Kalpathy-Cramer J, Jennings D, Emblem KE, Jain RK, Rosen BR, Wen PY, Sorensen AG, Batchelor TT, Gerstner ER.Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation.Oncologist. 2014 Jan;19(1):75-81.
  • Breuer J, Gutierrez J, Latchaw R, Lehr R, Sorensen AG.Gadobutrol in the central nervous system at three doses: results from a phase II, randomized, multicenter trial.J Magn Reson Imaging. 2014 Feb;39(2):410-8.
  • Batchelor TT, Gerstner ER, Emblem KE, Duda DG, Kalpathy-Cramer J, Snuderl M, Ancukiewicz M, Polaskova P, Pinho MC, Jennings D, Plotkin SR, Chi AS, Eichler AF, Dietrich J, Hochberg FH, Lu-Emerson C, Iafrate AJ, Ivy SP, Rosen BR, Loeffler JS, Wen PY, Sorensen AG, Jain RK.Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation.Proc Natl Acad Sci U S A. 2013 Nov 19;110(47):19059-64.
  • Emblem KE, Mouridsen K, Bjornerud A, Farrar CT, Jennings D, Borra RJ, Wen PY, Ivy P, Batchelor TT, Rosen BR, Jain RK, Sorensen AG.Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy.Nat Med. 2013 Sep;19(9):1178-83.
  • Batchelor TT, Mulholland P, Neyns B, Nabors LB, Campone M, Wick A, Mason W, Mikkelsen T, Phuphanich S, Ashby LS, Degroot J, Gattamaneni R, Cher L, Rosenthal M, Payer F, Jürgensmeier JM, Jain RK, Sorensen AG, Xu J, Liu Q, van den Bent M.Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.J Clin Oncol. 2013 Sep 10;31(26):3212-8.
  • Andronesi OC, Rapalino O, Gerstner E, Chi A, Batchelor TT, Cahill DP, Sorensen AG, Rosen BR.Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate.J Clin Invest. 2013 Sep 3;123(9):3659-63. Review.
  • Boxerman JL, Zhang Z, Safriel Y, Larvie M, Snyder BS, Jain R, Chi TL, Sorensen AG, Gilbert MR, Barboriak DP.Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study.Neuro Oncology. 2013 Jul;15(7):945-54.
  • Ratai EM, Zhang Z, Snyder BS, Boxerman JL, Safriel Y, McKinstry RC, Bokstein F, Gilbert MR, Sorensen AG, Barboriak DP.Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677.Neuro Oncology. 2013 May 3.
  • Hygino da Cruz LC, Rodriguez I, Domingues RC, Gasparetto EL, Sorensen AG.Pseudoprogression and Pseudoresponse: Imaging Challenges in the Assessment of Posttreatment Glioma.AJNR Am J Neuroradiol. 2011 Mar 31.
  • Farrar CT, Kamoun WS, Ley CD, Kim YR, Catana C, Kwon SJ, Rosen BR, Jain RK, Sorensen AG.Sensitivity of MRI Tumor Biomarkers to VEGFR Inhibitor Therapy in an Orthotopic Mouse Glioma Model.PLoS ONE. 2011;6(3):e17228.
  • Ramadan S, Andronesi OC, Stanwell P, Lin AP, Sorensen AG, Mountford CE.Use of in Vivo Two-dimensional MR Spectroscopy to Compare the Biochemistry of the Human Brain to That of Glioblastoma.Radiology. 2011 Feb 25.
  • Gerstner ER, Sorensen AG.Diffusion and diffusion tensor imaging in brain cancer.Semin Radiat Oncol. 2011 Apr;21(2):141-6.
  • di Tomaso E, Snuderl M, Kamoun WS, Duda DG, Auluck PK, Fazlollahi L, Andronesi OC, Frosch MP, Wen PY, Plotkin SR, Hedley-Whyte ET, Sorensen AG, Batchelor TT, Jain RK.Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape.Cancer Res. 2011 Jan 1;71(1):19-28.
  • Sorensen G, Stoddard A, Quintiliani L, Ebbeling C, Nagler E, Yang M, Pereira L, Wallace L.Tobacco use cessation and weight management among motor freight workers: results of the gear up for health study.Cancer Causes Control. 2010 Dec;21(12):2113-22.
  • Andronesi OC, Ramadan S, Mountford CE, Sorensen AG.Low-power adiabatic sequences for in vivo localized two-dimensional chemical shift correlated MR spectroscopy.Magn Reson Med. 2010 Dec;64(6):1542-56.
  • Nguyen KH, Subramanian SV, Sorensen G, Tsang K, Wright RJ.Influence of experiences of racial discrimination and ethnic identity on prenatal smoking among urban black and Hispanic women.J Epidemiol Community Health. 2010 Oct 25.
  • Sun PZ, Cheung JS, Wang E, Benner T, Sorensen AG.Fast multislice pH-weighted chemical exchange saturation transfer (CEST) MRI with Unevenly segmented RF irradiation.Magn Reson Med. 2010 Sep 24.
  • Quintiliani L, Yang M, Sorensen G.A process evaluation of tobacco-related outcomes from a telephone and print-delivered intervention for motor freight workers.Addict Behav. 2010 Nov;35(11):1036-9.
  • Chae SS, Kamoun WS, Farrar CT, Kirkpatrick ND, Niemeyer E, de Graaf AM, Sorensen AG, Munn LL, Jain RK, Fukumura D.Angiopoietin-2 Interferes with Anti-VEGFR-2- Induced Vessel Normalization and Survival Benefit in Mice Bearing Gliomas.Clin Cancer Res. 2010 Jul 15;16(14):3618-27.
  • Sapp AL, Kawachi I, Sorensen G, LaMontagne AD, Subramanian SV.Does workplace social capital buffer the effects of job stress? A cross-sectional, multilevel analysis of cigarette smoking among U.S. manufacturing workers.J Occup Environ Med. 2010 Jul;52(7):740-50.
  • Viswanath K, Ackerson LK, Sorensen G, Gupta PC.Movies and TV influence tobacco use in India: findings from a national survey.PLoS ONE. 2010;5(6):e11365.
  • Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, Benner T, Louis DN, Cohen KS, Chea H, Exarhopoulos A, Loeffler JS, Moses MA, Ivy P, Sorensen AG, Wen PY, Jain RK.Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.J Clin Oncol. 2010 Jun 10;28(17):2817-23.
  • Gerstner ER, Chen PJ, Wen PY, Jain RK, Batchelor TT, Sorensen G.Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib.Neuro Oncology. 2010 May;12(5):466-72.
  • Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM.Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group.J Clin Oncol. 2010 Apr 10;28(11):1963-72.
  • Farrar CT, Kamoun WS, Ley CD, Kim YR, Kwon SJ, Dai G, Rosen BR, di Tomaso E, Jain RK, Sorensen AG.In vivo validation of MRI vessel caliber index measurement methods with intravital optical microscopy in a U87 mouse brain tumor model.Neuro Oncology. 2010 Apr;12(4):341-50.
  • Andronesi OC, Ramadan S, Ratai EM, Jennings D, Mountford CE, Sorensen AG.Spectroscopic imaging with improved gradient modulated constant adiabaticity pulses on high-field clinical scanners.J Magn Reson. 2010 Apr;203(2):283-93.
  • Sorensen AG, Heiss WD.Advances in imaging 2009.Stroke. 2010 Feb;41(2):e91-2. Review.
  • Plotkin SR, Stemmer-Rachamimov AO, Barker FG, Halpin C, Padera TP, Tyrrell A, Sorensen AG, Jain RK, di Tomaso E.Hearing improvement after bevacizumab in patients with neurofibromatosis type 2.N Engl J Med. 2009 Jul 23;361(4):358-67.
  • Sorensen AG,Batchelor TT,Zhang WT,Chen PJ,Yeo P,Wang M,Jennings D,Wen PY,Lahdenranta J,Ancukiewicz M,di Tomaso E,Duda DG,Jain RK.A "Vascular Normalization Index" as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients.Cancer Res. 2009 Jul 1;69(13):5296-300.
  • Chi AS,Sorensen AG,Jain RK,Batchelor TT.Angiogenesis as a Therapeutic Target in Malignant Gliomas.Oncologist. 2009 Jun;14(6):621-36. Review.
  • Jain RK,Duda DG,Willett CG,Sahani DV,Zhu AX,Loeffler JS,Batchelor TT,Sorensen AG.Biomarkers of response and resistance to antiangiogenic therapy.Nat Rev Clin Oncol. 2009 Jun;6(6):327-338. Review.
  • Plotkin SR,Halpin C,Blakeley JO,Slattery WH 3rd,Welling DB,Chang SM,Loeffler JS,Harris GJ,Sorensen AG,McKenna MJ,Barker FG 2nd.Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma.J Neurooncol. 2009 May;93(1):61-77. Review.
  • Gerstner ER,Sorensen AG,Jain RK,Batchelor TT.Anti-vascular endothelial growth factor therapy for malignant glioma.Curr Neurol Neurosci Rep. 2009 May;9(3):254-62. Review.
  • Gerstner ER,Duda DG,di Tomaso E,Ryg PA,Loeffler JS,Sorensen AG,Ivy P,Jain RK,Batchelor TT.VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer.Nat Rev Clin Oncol. 2009 Apr;6(4):229-36. Review.
  • Kamoun WS,Ley CD,Farrar CT,Duyverman AM,Lahdenranta J,Lacorre DA,Batchelor TT,di Tomaso E,Duda DG,Munn LL,Fukumura D,Sorensen AG,Jain RK.Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice.J Clin Oncol. 2009 May 20;27(15):2542-52.
  • Gerstner ER,Sorensen AG,Jain RK,Batchelor TT.Advances in neuroimaging techniques for the evaluation of tumor growth, vascular permeability, and angiogenesis in gliomas.Curr Opin Neurol. 2008 Dec;21(6):728-35. Review.
  • Sorensen AG.Perfusion MR imaging: moving forward.Radiology. 2008 Nov;249(2):416-7.
  • Sun PZ, Benner T, Kumar A, Sorensen AG.Investigation of optimizing and translating pH-sensitive pulsed-chemical exchange saturation transfer (CEST) imaging to a 3T clinical scanner.Magn Reson Med. 2008 Oct;60(4):834-41.
  • Sorensen AG,Batchelor TT,Wen PY,Zhang WT,Jain RK.Response criteria for glioma.Nat Clin Pract Oncol. 2008 Nov;5(11):634-44. Review.
  • Sun PZ, Sorensen AG.Imaging pH using the chemical exchange saturation transfer (CEST) MRI: Correction of concomitant RF irradiation effects to quantify CEST MRI for chemical exchange rate and pH.Magn Reson Med. 2008 Aug;60(2):390-7.
  • Lynch TJ Jr,Blumenschein GR Jr,Engelman JA,Espinoza-Delgado I,Govindan R,Hanke J,Hanna NH,Heymach JV,Hirsch FR,Janne PA,Lilenbaum RC,Natale RB,Riely GJ,Sequist LV,Shapiro GI,Shaw A,Shepherd FA,Socinski M,Sorensen AG,Wakelee HA,Weitzman A.Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapy.J Thorac Oncol. 2008 Jun;3(6 Suppl 2):S107-12.
  • Uppoor RS, Mummaneni P, Cooper E, Pien HH, Sorensen AG, Collins J, Mehta MU, Yasuda SU.The use of imaging in the early development of neuropharmacological drugs: a survey of approved NDAs.Clin Pharmacol Ther. 2008 Jul;84(1):69-74.
  • Sorensen AG, Heiss WD.Advances in imaging 2007.Stroke. 2008 Feb;39(2):276-8. Review.
  • Sun PZ, Farrar CT, Sorensen AG.Correction for artifacts induced by B(0) and B(1) field inhomogeneities in pH-sensitive chemical exchange saturation transfer (CEST) imaging.Magn Reson Med. 2007 Dec;58(6):1207-15.
  • Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT.Angiogenesis in brain tumours.Nat Rev Neurosci. 2007 Aug;8(8):610-22. Review.
  • Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK.AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.Cancer Cell. 2007 Jan;11(1):83-95.
  • Cruz LC, Sorensen AG.Diffusion tensor magnetic resonance imaging of brain tumors.Magn Reson Imaging Clin N Am. 2006 May;14(2):183-202.
  • Sorensen AG.Magnetic resonance as a cancer imaging biomarker.J Clin Oncol. 2006 Jul 10;24(20):3274-81. Review.
  • Lorenz C, Benner T, Lopez CJ, Ay H, Zhu MW, Aronen H, Karonen J, Liu Y, Nuutinen J, Sorensen AG.Effect of using local arterial input functions on cerebral blood flow estimation.J Magn Reson Imaging. 2006 Jul;24(1):57-65.
  • Benner T, van der Kouwe AJ, Kirsch JE, Sorensen AG.Real-time RF pulse adjustment for B0 drift correction.Magn Reson Med. 2006 Jul;56(1):204-9.
  • Ning M, Furie KL, Koroshetz WJ, Lee H, Barron M, Lederer M, Wang X, Zhu M, Sorensen AG, Lo EH, Kelly PJ.Association between tPA therapy and raised early matrix metalloproteinase-9 in acute stroke.Neurology. 2006 May 23;66(10):1550-5.
  • Zhang WT, Mainero C, Kumar A, Wiggins CJ, Benner T, Purdon PL, Bolar DS, Kwong KK, Sorensen AG.Strategies for improving the detection of fMRI activation in trigeminal pathways with cardiac gating.Neuroimage. 2006 Jul 15;31(4):1506-12.
  • Ay H, Koroshetz WJ, Benner T, Vangel MG, Melinosky C, Arsava EM, Ayata C, Zhu M, Schwamm LH, Sorensen AG.Neuroanatomic correlates of stroke-related myocardial injury.Neurology. 2006 May 9;66(9):1325-9.
  • Benner T, Wisco JJ, van der Kouwe AJ, Fischl B, Vangel MG, Hochberg FH, Sorensen AG.Comparison of manual and automatic section positioning of brain MR images.Radiology. 2006 Apr;239(1):246-54.
  • Nimsky C, Ganslandt O, Merhof D, Sorensen AG, Fahlbusch R.Intraoperative visualization of the pyramidal tract by diffusion-tensor-imaging-based fiber tracking.Neuroimage. 2006 May 1;30(4):1219-29.
  • Leclerc X, Fichten A, Gauvrit JY, Riegel B, Steinling M, Lejeune JP, Pruvo JP.Symptomatic vasospasm after subarachnoid haemorrhage: assessment of brain damage by diffusion and perfusion-weighted MRI and single-photon emission computed tomography.Neuroradiology. 2002 Jul;44(7):610-6.
  • Leclerc X, Huisman TA, Sorensen AG.The potential of proton magnetic resonance spectroscopy ((1)H-MRS) in the diagnosis and management of patients with brain tumors.Curr Opin Oncol. 2002 May;14(3):292-8.
  • Provenzale JM, Wang GR, Brenner T, Petrella JR, Sorensen AG.Comparison of permeability in high-grade and low-grade brain tumors using dynamic susceptibility contrast MR imaging.AJR Am J Roentgenol. 2002 Mar;178(3):711-6.
  • Yamada K, Wu O, Gonzalez RG, Bakker D, Østergaard L, Copen WA, Weisskoff RM, Rosen BR, Yagi K, Nishimura T, Sorensen AG.Magnetic resonance perfusion-weighted imaging of acute cerebral infarction: effect of the calculation methods and underlying vasculopathy.Stroke. 2002 Jan;33(1):87-94.
  • Ostergaard L, Chesler DA, Weisskoff RM, Sorensen AG, Rosen BR.Modeling cerebral blood flow and flow heterogeneity from magnetic resonance residue data.J Cereb Blood Flow Metab. 1999 Jun;19(6):690-9.
  • Sorensen AG, Copen WA, Ostergaard L, Buonanno FS, Gonzalez RG, Rordorf G, Rosen BR, Schwamm LH, Weisskoff RM, Koroshetz WJ.Hyperacute stroke: simultaneous measurement of relative cerebral blood volume, relative cerebral blood flow, and mean tissue transit time.Radiology. 1999 Feb;210(2):519-27.
  • Sorensen AG.The link between diagnosis and therapy.AJNR Am J Neuroradiol. 1999 Jan;20(1):3-4.
  • Ostergaard L, Hochberg FH, Rabinov JD, Sorensen AG, Lev M, Kim L, Weisskoff RM, Gonzalez RG, Gyldensted C, Rosen BR.Early changes measured by magnetic resonance imaging in cerebral blood flow, blood volume, and blood-brain barrier permeability following dexamethasone treatment in patients with brain tumors.J Neurosurg. 1999 Feb;90(2):300-5.
  • González RG, Schaefer PW, Buonanno FS, Schwamm LH, Budzik RF, Rordorf G, Wang B, Sorensen AG, Koroshetz WJ.Diffusion-weighted MR imaging: diagnostic accuracy in patients imaged within 6 hours of stroke symptom onset.Radiology. 1999 Jan;210(1):155-62.
  • Schwamm LH, Koroshetz WJ, Sorensen AG, Wang B, Copen WA, Budzik R, Rordorf G, Buonanno FS, Schaefer PW, Gonzalez RG.Time course of lesion development in patients with acute stroke: serial diffusion- and hemodynamic-weighted magnetic resonance imaging.Stroke. 1998 Nov;29(11):2268-76.
  • Barest GD, Sorensen AG, Gonzalez RG.Magnetic resonance imaging of cerebral infarction.Top Magn Reson Imaging. 1998 Aug;9(4):199-207.
  • Sorensen AG.Investigating multiple sclerosis with spectroscopic imaging: harbinger of a new paradigm.AJNR Am J Neuroradiol. 1998 Jun-Jul;19(6):1002-3.
  • Rordorf G, Koroshetz WJ, Copen WA, Cramer SC, Schaefer PW, Budzik RF, Schwamm LH, Buonanno F, Sorensen AG, Gonzalez G.Regional ischemia and ischemic injury in patients with acute middle cerebral artery stroke as defined by early diffusion-weighted and perfusion-weighted MRI.Stroke. 1998 May;29(5):939-43.
  • Cutrer FM, Sorensen AG, Weisskoff RM, Ostergaard L, Sanchez del Rio M, Lee EJ, Rosen BR, Moskowitz MA.Perfusion-weighted imaging defects during spontaneous migrainous aura.Ann Neurol. 1998 Jan;43(1):25-31.
  • Lev MH, Kulke SF, Sorensen AG, Boxerman JL, Brady TJ, Rosen BR, Buchbinder BR, Weisskoff RM.Contrast-to-noise ratio in functional MRI of relative cerebral blood volume with sprodiamide injection.J Magn Reson Imaging. 1997 May-Jun;7(3):523-7.
  • Sorensen AG, Tievsky AL, Ostergaard L, Weisskoff RM, Rosen BR.Contrast agents in functional MR imaging.J Magn Reson Imaging. 1997 Jan-Feb;7(1):47-55.
  • Warach S, Mosley M, Sorensen AG, Koroshetz W.Time course of diffusion imaging abnormalities in human stroke.Stroke. 1996 Jul;27(7):1254-6.
  • Sorensen AG, Buonanno FS, Gonzalez RG, Schwamm LH, Lev MH, Huang-Hellinger FR, Reese TG, Weisskoff RM, Davis TL, Suwanwela N, Can U, Moreira JA, Copen WA, Look RB, Finklestein SP, Rosen BR, Koroshetz WJ.Hyperacute stroke: evaluation with combined multisection diffusion-weighted and hemodynamically weighted echo-planar MR imaging.Radiology. 1996 May;199(2):391-401.
  • Sorensen AG, Wray SH, Weisskoff RM, Boxerman JL, Davis TL, Caramia F, Kwong KK, Stern CE, Baker JR, Breiter H.Functional MR of brain activity and perfusion in patients with chronic cortical stroke.AJNR Am J Neuroradiol. 1995 Oct;16(9):1753-62.